Efficacy and safety of candidate biosimilar CT-P41 versus reference denosumab: a double-blind, randomized, active-controlled, Phase 3 trial in postmenopausal women with osteoporosis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Efficacy and safety of candidate biosimilar CT-P41 versus reference denosumab: a double-blind, randomized, active-controlled, Phase 3 trial in postmenopausal women with osteoporosis ; day:23 ; month:7 ; year:2024 ; pages:1-12
Osteoporosis international ; (23.7.2024), 1-12
- Creator
-
Reginster, Jean-Yves
Czerwinski, Edward
Wilk, Krzysztof
Borowy, Przemysław
Strzelecka, Anna
Budlewski, Tomasz
Janowska-Maus, Monika
Szymanowski, Krzysztof
Kwiatek, Joanna
Postol, Svitlana
Põder, Airi
Supronik, Jerzy
Kim, SungHyun
Suh, JeeHye
Han, NooRi
Kim, NaHyun
Bae, SeoHee
Silverman, Stuart L.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00198-024-07161-x
- URN
-
urn:nbn:de:101:1-2410090808386.663967623685
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
01.08.2002, 6:03 PM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Reginster, Jean-Yves
- Czerwinski, Edward
- Wilk, Krzysztof
- Borowy, Przemysław
- Strzelecka, Anna
- Budlewski, Tomasz
- Janowska-Maus, Monika
- Szymanowski, Krzysztof
- Kwiatek, Joanna
- Postol, Svitlana
- Põder, Airi
- Supronik, Jerzy
- Kim, SungHyun
- Suh, JeeHye
- Han, NooRi
- Kim, NaHyun
- Bae, SeoHee
- Silverman, Stuart L.
- SpringerLink (Online service)
Other Objects (12)
Randomized Double-Blind Comparative Study of First Global Denosumab Biosimilar in Oncology
Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis: a meta-analysis
Postmenopausal osteoporosis
Real-world cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis in Taiwan
Efficacy and safety of the biosimilar denosumab candidate (Arylia) compared to the reference product (Prolia®) in postmenopausal osteoporosis: a phase III, randomized, two-armed, double-blind, parallel, active-controlled, and noninferiority clinical trial
Medication-taking behaviour in Bulgarian women with postmenopausal osteoporosis treated with denosumab or monthly oral bisphosphonates
Clinical effects of switching from minodronate to denosumab treatment in patients with postmenopausal osteoporosis: a retrospective study
Effectiveness of denosumab for fracture prevention in real-world postmenopausal women with osteoporosis: a retrospective cohort study
Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study
Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study
Real-world Management of Women with Postmenopausal Osteoporosis Treated with Denosumab: A Prospective Observational Study in the Czech Republic and Slovakia
Quality of life in post-menopausal osteoporosis
Randomized Double-Blind Comparative Study of First Global Denosumab Biosimilar in Oncology
Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis: a meta-analysis
Postmenopausal osteoporosis
Real-world cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis in Taiwan
Efficacy and safety of the biosimilar denosumab candidate (Arylia) compared to the reference product (Prolia®) in postmenopausal osteoporosis: a phase III, randomized, two-armed, double-blind, parallel, active-controlled, and noninferiority clinical trial
Medication-taking behaviour in Bulgarian women with postmenopausal osteoporosis treated with denosumab or monthly oral bisphosphonates
Clinical effects of switching from minodronate to denosumab treatment in patients with postmenopausal osteoporosis: a retrospective study
Effectiveness of denosumab for fracture prevention in real-world postmenopausal women with osteoporosis: a retrospective cohort study
Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study
Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study
Real-world Management of Women with Postmenopausal Osteoporosis Treated with Denosumab: A Prospective Observational Study in the Czech Republic and Slovakia
Quality of life in post-menopausal osteoporosis
Randomized Double-Blind Comparative Study of First Global Denosumab Biosimilar in Oncology
Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis: a meta-analysis
Postmenopausal osteoporosis
Real-world cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis in Taiwan
Efficacy and safety of the biosimilar denosumab candidate (Arylia) compared to the reference product (Prolia®) in postmenopausal osteoporosis: a phase III, randomized, two-armed, double-blind, parallel, active-controlled, and noninferiority clinical trial
Medication-taking behaviour in Bulgarian women with postmenopausal osteoporosis treated with denosumab or monthly oral bisphosphonates
Clinical effects of switching from minodronate to denosumab treatment in patients with postmenopausal osteoporosis: a retrospective study
Effectiveness of denosumab for fracture prevention in real-world postmenopausal women with osteoporosis: a retrospective cohort study
Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study
Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study
Real-world Management of Women with Postmenopausal Osteoporosis Treated with Denosumab: A Prospective Observational Study in the Czech Republic and Slovakia